Two weeks ago, Japan became the first country in the world to approve a new type of

self-amplifying mRNA vaccine, otherwise known as an SA mRNA vaccine.

Specifically, a company called Meiji Saka Farma, that's based out in Tokyo, released

a statement on November 28th, announcing the fact that they've been given official

government approval to manufacture and market a Replicon vaccine, which is the first

ever to use self-amplifying mRNA technology.

Here's part of what their statement said, quote,

Meiji Holdings announces that it's subsidiary.

Meiji Saka Farma has received approval for the manufacturing and marketing of Kostavi,

for muscular injection, a self-amplifying mRNA vaccine against COVID-19 from the Ministry

of Health, Labor, and Welfare in Japan.

Kostavi is indicated for prevention of COVID-19 by primary immunization, two doses, and

booster immunization in adults.

This is the world's first approved Replicon vaccine, applying self-amplifying mRNA technology.

Now obviously, I'm sure that almost everyone watching this video right now has the very

same question in their mind.

What in the world is a self-amplifying mRNA vaccine?

Well, to answer that question, let's compare this new vaccine to the quote-unquote normal

mRNA vaccines, like the ones from Pfizer and Moderna.

Here's how the normal mRNA vaccines work.

Whether it's Pfizer or Moderna, this is the basic outline.

You have a strand of modified mRNA, which contains in it a sequence for making the spike protein

...